Entrepreneurial spirit takes on new meaning as Olivier Goy, diagnosed with amyotrophic lateral sclerosis (ALS) since 2020, continues to lead the fintech company October and push for progress in ALS research. Clamped to his wheelchair due to the debilitating effects of the disease, Goy exemplifies how determination can redefine one’s life and purpose even under the direst circumstances.
ALS, also known as Lou Gehrig's disease, is marked by the progressive degeneration of motor neurons, leading to muscle atrophy, paralysis, and, eventually, respiratory failure. The situation has grown dire over the years, with reports indicating the number of cases has doubled within the past two decades.
Despite the odds stacked against him, Goy discovered the vast potential remaining within his mind and spirit. "My mind remained intact," he stated during a recent interview with BFM Business. Initially overwhelmed by the diagnosis, he quickly adapted to the new reality, realizing he could still contribute significantly to both business and medical research.
Instead of succumbing to despair, Goy stepped up as president of October, the fintech company he founded, where he continues to drive innovation and support his team from his wheelchair. He also chairs the association France Fintech and proudly serves as the ambassador of the Institut du cerveau, one of Europe’s largest neurological research centers.
Goy’s approach to life emphasizes utility and purpose. "It's simple, I want to make useful the time I have left," he asserted, demonstrating his commitment to improving the quality of life for fellow ALS patients through tangible action.
Since his diagnosis, Goy has mobilized charitable efforts, successfully raising over 2.5 million euros for the Institut du cerveau, aimed at advancing research on ALS and related diseases. Each euro serves to fund important studies as scientists race against time to find potential therapies for this devastating condition.
His latest initiative is the launch of Invincible été, a new philanthropic fund dedicated to financing ALS research. This fund is structured to allow generous donors to invest significantly, with the goal of maintaining the necessary funds for ALS research whilst also encouraging return on investment. Goy detailed the fund's aspirations: "At cruising speed, a fund of 20 million euros aims to generate one million euros of annual income for research." This approach presents an innovative mix of philanthropy and investment, targeting the persistent challenges faced within ALS research.
Financial contributions will be directed to selected European researchers and projects focusing on ALS, following stringent evaluations coordinated by the Institut du cerveau. With over thirty researchers at their disposal, Goy's initiative could pave the way for breakthroughs, as they pursue funds for new projects often costing upwards of 200,000 euros.
"We respond to calls for projects, so we ask for funding to develop additional projects," noted Séverine Boillée, head of one such research unit. The hope is not only to continue studies but also to expand the scope of research to cover the newly identified 30 genes associated with ALS, double the number identified just ten years ago.
While currently there exists no cure for ALS, Goy embodies the spirit of resilience and entrepreneurship through his relentless pursuit of knowledge and support for ALS research. He has turned what could have been a life-defining setback—his diagnosis—into fuel for social change, demonstrating the power of hope and innovation.
Olivier Goy's story is one of defiance against illness and unwavering commitment to improving lives, blending entrepreneurship with philanthropy. His efforts remind us of the significant role individuals can play, even when life poses the most significant challenges. By continuing to push for advancements and contributing to ALS research, Goy not only advocates for himself but stands as a beacon of hope for many others battling the disease.